Sort   by:  
 Page size 
UnknownEvaluating rilzabrutinib in the treatment of immune thrombocytopenia.
Not available
S-EPMC12427540 | biostudies-literature
UnknownQuality of life after COVID-19 without hospitalisation: Good overall, but reduced in some dimensions.
Not available
S-EPMC7834148 | biostudies-literature
UnknownThe feasibility of self-performing measurements of peripheral oxygen saturation and respiratory exercises in home-isolated COVID-19 patients-a single-arm prospective trial.
Not available
S-EPMC10693052 | biostudies-literature
UnknownNew score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs.
Not available
S-EPMC6307577 | biostudies-literature
UnknownComparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Not available
S-EPMC7073510 | biostudies-literature
UnknownP1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR
Not available
S-EPMC10429905 | biostudies-literature
UnknownThrombopoietin receptor agonists: ten years later.
Not available
S-EPMC6545830 | biostudies-literature
UnknownPrevalence and Risk Factors for Post-Traumatic Stress in Hospitalized and Non-Hospitalized COVID-19 Patients.
Not available
S-EPMC7924607 | biostudies-literature
UnknownCognitive function in non-hospitalized patients 8-13 months after acute COVID-19 infection: A cohort study in Norway.
Not available
S-EPMC9394790 | biostudies-literature
UnknownP1638: EARLY USE OF ELTROMBOPAG IN ADULT PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE CORTICOSTEROID THERAPY – AN AD HOC ANALYSIS OF THE TAPER TRIAL RESULTS
Not available
S-EPMC9429140 | biostudies-literature
Sort   by:  
 Page size